|
1) Sinisalo M, Hietaharju A, Sauranen J, et al. Thalidomide in POEMS syndrome: case report. Am J Hematol. 2004; 76: 66-8
|
|
|
|
2) Kim SY, Lee SA, Ryoo HM, et al. Thalidomide for POEMS syndrome. Ann Hematol. 2006; 85: 545-6
|
|
|
|
|
|
3) Kuwabara S, Misawa S, Kanai K, et al. Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. J Neurol Neurosurg Psychiatry. 2008; 79: 1255-7
|
|
|
|
|
|
4) Marjanovic BD, Stojanov LM, Zdravkovic DS, et al. Rasmussen syndrome and long-term response to thalidomide. Pediatr Neurol. 2003; 29: 151-6
|
|
|
|
|
|
5) Hoyle JC, Newton HB, Katz S. Prognosis of refractory neurosarcoidosis altered by thalidomide: a case report. J Med Case Reports. 2008; 2: 27
|
|
|
|
|
|
6) Corrêa JO, Aarestrup BJ, Aarestrup FM. Effect of thalidomide and pentoxifylline on experimental autoimmune encephalomyelitis (EAE). Exp Neurol. 2010 Apr 18. [Epub ahead of print]
|
|
|
|
|
|
7) Palencia G, Calderon A, Sotelo J. Thalidomide inhibits pentylenetetrazole-induced seizures. J Neurol Sci. 2007; 258: 128-31
|
|
|
|
|
|
8) 柏森良二. サリドマイド物語. 東京: 医歯薬出版; 1997
|
|
|
|
|
|
9) Fenelli M, Samiento R, Gattuso D, et al. Thalidmide: a anticancer drug？ Expert Opin Investig Drugs. 2003; 12: 1211-25
|
|
|
|
|
|
10) Kuwabara S, Misawa S, Kanai K, et al. Neurologic improvement after peripheral blood stem cell transplantation in POEMS syndrome. Neurology. 2008; 71: 1691-5
|
|
|
|
|
|
11) 免疫性神経疾患に関する調査研究班. HP http://nimmunol.umin.jp/index.html
|
|
|
|
|
|
12) Sastry PS. Inhibition of TNF-alpha synthesis with thalidomide for prevention of acute exacerbations and altering the natural history of multiple sclerosis. Med Hypotheses. 1999; 53: 76-7
|
|
|
|
|
|
13) Contino-Pépin C, Parat A, Périno S, et al. Preliminary biological evaluations of new thalidomide analogues for multiple sclerosis application. Bioorg Med Chem Lett. 2009; 19: 878-81
|
|
|
|
|
|
14) Yasui K, Yashiro M, Tsuge M, et al. Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: its possible action and mechanism. Arthritis Rheum. 2010; 62: 250-7
|
|
|
|
|
|
15) Alkam T, Nitta A, Mizoguchi H, et al. Restraining tumor necrosis factor-alpha by thalidomide prevents the amyloid beta-induced impairment of recognition memory in mice. Behav Brain Res. 2008; 189: 100-6
|
|
|
|
|
|
16) Ryu JK, McLarnon JG. Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-alpha in an animal model of inflamed Alzheimerʼs disease brain. Neurobiol Dis. 2008; 29: 254-66
|
|
|
|
|
|
17) Stommel EW, Cohen JA, Fadul CE, et al. Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph Lateral Scler. 2009; 10: 393-404
|
|
|
|
|